Mayo Clinic named national site for Convalescent Plasma Expanded Access Program

ROCHESTER, Minn. -- Mayo Clinic will be the lead institution providing coordinated access to investigational convalescent plasma for hospitalized patients with severe or life-threatening COVID-19, or those at high risk of progression to severe or life-threatening disease. The Food and Drug Administration (FDA) announced the designation on Friday, April 3. Convalescent plasma refers to blood [...]
Source: Mayo Clinic Business News - Category: Pharmaceuticals Source Type: news